Skip to main content

Table 2 Changes of variables related with glucose metabolism after 12 weeks

From: Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

 

Baseline (mean±s.d.)

12 weeks (mean±s.d.)

Mean changes from baseline (95% CI)

★Difference in mean change (95% CI)

HbA1c (%)

    

Liraglutide added

8.79 ± 0.86

6.88 ± 0.64

-1.9 (-2.10, -1.72) **

-0.14 (-0.41, 0.13)

Insulin increaing

8.69 ± 0.91

6.93 ± 0.63

-1.77 (-2.00, -1.56) **

 

PBG (mmol/L)

    

Liraglutide added

8.36 ± 0.93

6.79 ± 0.48

-1.56 (-1.80, -1.33) **

0.13 (0.15, -0.16)

Insulin increasing

8.41 ± 0.86

6.72 ± 0.46

-1.69 (-1.90, -1.48) **

 

P2BG (mmol/L)

    

Liraglutide added

13.76 ± 1.92

8.39 ± 1.17

-5.40 (-5.8, -4.92) **

-0.83 (-1.59, -0.07) #

Insulin increasing

13.80 ± 1.96

9.26 ± 1.19

-4.54 (-5.0, -4.0) **

 

Body weight (kg)

    

Liraglutide added

88.6 ± 11.8

82.9 ± 11.2

-5.62 (-6.51, -4.73) **

-7.6 (-8.67, -6. 57) ##

Insulin increasing

86.3 ± 10.3

88.3 ± 10.4

2.00 (1.52, 2.48) **

 

BMI (kg/m2)

    

Liraglutide added

30.4 ± 3.21

28.4 ± 3.04

-1.93 (-2.24, -1.63) **

-2.63 (-2.99, -2.67) ##

Insulin increasing

30.3 ± 2.98

31.00 ± 2.91

0.70 (0.53, 0.86) **

 

Waist Circumference (cm)

    

Liraglutide added

105.6 ± 12.6

99.9 ± 11.8

-5.70 (-6.5, -5.0) **

-7.5 (-8.4, -6.6) ##

Insulin increasing

104.6 ± 10.5

106.3 ± 10.4

1.76 (1.30, 2.23) **

 
  1. ★Difference in mean change calculated as Liraglutide minus Insulin; CI, confidence interval; **p<0.01 for mean change from baseline in liraglutide and insulin; # p<0.05, ## p<0.01 for the between-treatment difference.